Intellia Therapeutics
NTLA
$11.86
-9.05%
Intellia Therapeutics is a gene-editing company focused on developing CRISPR/Cas9-based therapeutics for genetically defined diseases, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. As a pioneer in in vivo CRISPR therapies, it holds a distinct competitive position with collaborations including Regeneron and Novartis. The current investor narrative centers on the successful Phase 3 trial for its lead CRISPR treatment, which has validated the technology and driven a major re-rating, with the stock up over 70% year-to-date amid expectations of a commercial launch.…
NTLA
Intellia Therapeutics
$11.86
Related headlines
Investment Opinion: Should I buy NTLA Today?
Rating: Hold. The thesis is that Intellia's Phase 3 success has de-risked the platform and driven a re-rating, but the stock's premium valuation and pre-revenue status limit upside until commercial revenue materializes. The analyst consensus is bullish, but the wide estimate range signals high uncertainty.
Supporting Evidence: The trailing PS ratio of 14.4x is 140% above the biotech industry average of ~6x, indicating the market is pricing in significant future revenue. Revenue growth is expected to be explosive, with estimates of $2.72 billion next fiscal year, but current revenue is zero. The gross margin of 76.5% suggests high profitability potential, but the negative operating margin of -652% shows the company is still in heavy investment mode. Free cash flow is negative, and the company has no dividend. The implied upside to analyst targets is not directly calculable, but the average EPS estimate of $8.97 implies a forward P/E of 1.6x, which is extremely low if achieved.
Risks & Conditions: The biggest risks are commercial adoption failure, pipeline setbacks, and valuation compression. This Hold would upgrade to Buy if the company reports positive revenue in the next quarterly filing or if the stock pulls back to a PS ratio below 10x (around $10). It would downgrade to Sell if a key trial fails or if revenue guidance disappoints. Overall, the stock is overvalued relative to its current financials but fairly valued if the revenue estimates are achieved. Investors should wait for a better entry point or confirmation of commercial success.
Sign up to view all
NTLA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The Phase 3 success is a significant positive, but the stock's premium valuation and pre-revenue status create a balanced risk/reward. The wide analyst estimate range underscores the binary nature of the investment. The key factor to watch is commercial revenue; if it meets or exceeds expectations, the stock could rally toward $20-25. If it disappoints, the stock could fall below $10. The high beta means the stock is also sensitive to macro conditions, adding another layer of uncertainty. The stance would upgrade to bullish if the company reports positive revenue with strong gross margins, and downgrade to bearish if a pipeline setback occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intellia Therapeutics's 12-month outlook, with a consensus price target around $25.68 and implied upside of +116.6% versus the current price.
Average Target
$25.68
0 analysts
Implied Upside
+116.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$8 - $95
Analyst target range
Six analysts cover Intellia, with a consensus recommendation leaning bullish. The average estimated EPS is $8.97, implying significant profitability expectations, though the range is wide from -$2.20 to $78.80, reflecting high uncertainty. The average revenue estimate is $2.72 billion, with a low of $114 million and a high of $19.0 billion, indicating divergent views on commercial success. The implied upside from the current price of $14.22 to the average target is not directly calculable without price targets, but the EPS estimates suggest a forward PE of 1.6x based on the average, which is extremely low if achieved. The wide range in estimates signals high uncertainty; the low end implies limited revenue and continued losses, while the high end assumes blockbuster sales. The recent news highlights a Wall Street re-rating following Phase 3 success, suggesting analysts may be upgrading. The lack of explicit price targets in the data limits precision, but the consensus appears bullish on the technology's potential.
Drowning in data?
Find the real signal!
Bulls vs Bears: NTLA Investment Factors
Intellia Therapeutics presents a high-risk, high-reward opportunity. The bull case is anchored by the successful Phase 3 trial, which validates its in vivo CRISPR platform and opens the door to a multi-billion-dollar market, with analysts projecting $2.72 billion in revenue. The strong balance sheet and high gross margins support the thesis. However, the bear case highlights that the company is pre-revenue, burning cash, and trading at a 140% premium to biotech peers based on PS ratio. The wide analyst estimate range underscores the binary nature of the stock—success could yield massive returns, but any clinical or commercial setback could lead to severe losses. The single most important tension is whether the Phase 3 success translates into commercial adoption and revenue growth; if it does, the stock could double, but if not, it could fall back to the 52-week low of $7.95. Currently, the bull case has stronger evidence given the recent validation, but the risk is substantial.
Bullish
- Phase 3 Success Validates CRISPR Platform: The successful Phase 3 trial for its lead CRISPR treatment has de-risked the technology and driven a major re-rating, with the stock up over 70% year-to-date. This validation positions Intellia for a potential commercial launch, with estimated revenue of $2.72 billion next fiscal year.
- Strong Balance Sheet with Low Debt: Intellia has a current ratio of 5.08 and a debt-to-equity ratio of 0.14, indicating ample liquidity and minimal leverage. This financial strength provides a multi-year cash runway to fund operations and pipeline development without near-term dilution risk.
- High Gross Margin Potential: The company's gross margin stands at 76.5%, reflecting the high profitability potential of CRISPR-based therapies once commercialized. This margin profile is typical of successful biotech products and supports long-term earnings power.
- Analyst Consensus Bullish on Upside: With six analysts covering the stock, the consensus is bullish, and the average estimated EPS of $8.97 implies a forward P/E of just 1.6x at the current price. Even the low EPS estimate of -$2.20 suggests limited downside, while the high estimate of $78.80 reflects massive upside potential.
Bearish
- Pre-Revenue with Negative Cash Flow: Intellia has zero current revenue and a negative free cash flow (PCF ratio of -2.79), meaning it burns cash to fund R&D. The net margin of -610% and operating margin of -652% highlight the heavy spending required before any product launch.
- Extreme Valuation Premium vs. Peers: The trailing PS ratio of 14.4x and EV/Sales of 28.2x are far above the biotech industry average PS of ~6x, implying a 140% premium. This valuation assumes successful commercialization and leaves no room for pipeline setbacks or competitive threats.
- High Volatility and Speculative Risk: With a beta of 1.77, the stock is 77% more volatile than the market, amplifying downside risk. The 52-week range of $7.95 to $28.25 shows the stock can lose over 70% from peak to trough, as evidenced by the historical max drawdown of -71.27%.
- Wide Analyst Estimate Dispersion: Revenue estimates range from $114 million to $19.0 billion, and EPS estimates from -$2.20 to $78.80, reflecting extreme uncertainty about commercial adoption. This wide dispersion means the stock could miss expectations significantly, leading to sharp sell-offs.
NTLA Technical Analysis
The stock is in a strong recovery uptrend, with a 1-year price change of +16.9% and currently trading at 50.3% of its 52-week range ($7.95 to $28.25). The price sits at $14.22, well above the 52-week low but still 49.7% below the high, suggesting room for further upside if momentum continues. The 6-month change of +36.9% confirms the upward trajectory, though the stock remains below the midpoint of its range, indicating potential for trend continuation. Short-term momentum is accelerating, with a 1-month change of +16.5% outpacing the 3-month change of +5.4%, signaling strengthening near-term buying pressure. The relative strength over 1 month is +12.4% versus the S&P 500, while the 1-year relative strength is -3.7%, indicating the stock is catching up after underperformance. The 52-week high of $28.25 represents key resistance, while the 52-week low of $7.95 provides support. A breakout above $28.25 would signal a new uptrend, while a breakdown below $7.95 would negate the recovery. With a beta of 1.77, the stock is 77% more volatile than the market, amplifying both upside and downside risks.
Beta
1.77
1.77x market volatility
Max Drawdown
-71.3%
Largest decline past year
52-Week Range
$8-$28
Price range past year
Annual Return
-0.8%
Cumulative gain past year
| Period | NTLA Return | S&P 500 |
|---|---|---|
| 1m | -18.5% | +0.1% |
| 3m | -20.7% | +5.7% |
| 6m | -5.1% | +8.5% |
| 1y | -0.8% | +20.3% |
| ytd | +28.8% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTLA Fundamental Analysis
Intellia is pre-revenue, with no quarterly revenue reported, and the trailing twelve-month revenue is effectively zero, as the company has not yet commercialized any product. The estimated revenue for the next fiscal year is $2.72 billion, reflecting expectations from a potential launch, but current revenue is negligible. The company is unprofitable, with a trailing EPS of -$0.42 and a net margin of -610%, indicating significant operating losses. Gross margin is 76.5%, suggesting high gross profit potential once revenue materializes, but operating margin is -652%, highlighting heavy R&D and SG&A spending. The balance sheet is healthy, with a current ratio of 5.08, indicating ample liquidity to cover short-term obligations. Debt-to-equity is low at 0.14, and the company has no dividend, preserving cash for R&D. However, free cash flow is negative, as indicated by a PCF ratio of -2.79, meaning the company relies on external financing or existing cash reserves to fund operations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTLA Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 14.4x, while forward PS is not calculable due to zero current revenue. The EV/Sales multiple of 28.2x further underscores the premium valuation. Compared to the biotechnology industry average PS ratio of approximately 6x, Intellia trades at a 140% premium, reflecting market expectations for future revenue from its CRISPR pipeline. The PEG ratio of 0.09 suggests that the stock is cheap relative to expected earnings growth, but this is based on highly uncertain estimates. Historical valuation data is not available, but the current PS ratio is elevated relative to pre-clinical stages, indicating the market is pricing in successful commercialization. The premium is justified by the potential of a first-in-class in vivo CRISPR therapy, but it also implies high execution risk.
PE
-2.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intellia's primary financial risk is its pre-revenue status and negative cash flow. With zero current revenue and a net margin of -610%, the company relies on external financing or existing cash reserves to fund operations. The current ratio of 5.08 provides a cushion, but the negative free cash flow (PCF ratio -2.79) means the company is burning through cash. If the commercial launch is delayed or less successful than expected, the company may need to raise capital through dilutive equity offerings, pressuring the stock. Additionally, the operating margin of -652% highlights the heavy R&D spending required, which could lead to continued losses for several years.
Market & Competitive Risks: The stock trades at a significant premium to the biotech industry average PS ratio of ~6x, with a trailing PS of 14.4x and EV/Sales of 28.2x. This premium leaves little room for error; any negative news could trigger a valuation compression. The beta of 1.77 indicates high sensitivity to market movements, and the stock has underperformed the S&P 500 by 3.7% over the past year, suggesting it is not yet fully participating in broader market rallies. Competitive risks include other gene-editing companies like CRISPR Therapeutics and Editas Medicine, as well as traditional therapies that may compete with Intellia's pipeline. Regulatory headwinds could also arise, as CRISPR-based therapies face scrutiny over long-term safety and ethical concerns.
Worst-Case Scenario: The most damaging scenario would be a clinical setback, such as safety issues in ongoing trials or a failure to achieve commercial adoption. If the lead product fails to gain regulatory approval or faces competition that limits market share, the stock could collapse. In this scenario, the realistic downside is to the 52-week low of $7.95, representing a -44% decline from the current price of $14.215. The historical max drawdown of -71.27% suggests even deeper losses are possible if the entire pipeline is questioned. An investor could lose up to 44% of their investment if the stock revisits its low, and potentially more if the company's viability is threatened.
FAQ
The key risks are: 1) Commercial execution risk – the company has zero revenue and must successfully launch its lead product; if adoption is slow, the stock could fall. 2) Valuation risk – the PS ratio of 14.4x is a 140% premium to peers, leaving no margin for error. 3) Pipeline risk – any clinical setback in other programs could damage credibility. 4) Financing risk – with negative free cash flow (PCF ratio -2.79), the company may need to dilute shareholders if cash burn continues. 5) Macro risk – with a beta of 1.77, the stock is highly sensitive to market downturns. The most severe risk is a commercial failure, which could drive the stock to the 52-week low of $7.95, a 44% decline from current levels.
The 12-month forecast is highly uncertain, with three scenarios: Bull case (25% probability) – price target $25-$30, driven by rapid commercial adoption and pipeline progress. Base case (50% probability) – price target $14-$20, as the company transitions to commercial stage with moderate revenue. Bear case (25% probability) – price target $8-$12, if commercial launch disappoints or a pipeline setback occurs. The base case is most likely, assuming the lead product meets analyst consensus of $2.72 billion in revenue. However, the wide estimate range means the stock could move significantly in either direction. Investors should monitor quarterly revenue reports and regulatory updates for signs of which scenario is unfolding.
NTLA is overvalued relative to its current financials but potentially undervalued relative to future earnings. The trailing PS ratio of 14.4x is 140% above the biotech industry average of ~6x, indicating the market is pricing in significant future revenue. The EV/Sales multiple of 28.2x further underscores the premium. However, the PEG ratio of 0.09 suggests the stock is cheap relative to expected earnings growth, though this is based on highly uncertain estimates. The average EPS estimate of $8.97 implies a forward P/E of 1.6x, which is extremely low if achieved. The valuation implies the market expects successful commercialization, but any disappointment could lead to a sharp de-rating. Overall, the stock is fairly valued only if the company meets its revenue targets; otherwise, it is overvalued.
NTLA is a high-risk, high-reward stock that may be suitable for aggressive investors with a long-term horizon. The successful Phase 3 trial has validated its CRISPR platform, and analysts project $2.72 billion in revenue next year, implying a forward P/E of just 1.6x. However, the stock is pre-revenue, trades at a PS ratio of 14.4x (140% premium to biotech peers), and has a beta of 1.77, amplifying downside risk. The wide analyst estimate range (revenue from $114M to $19B) highlights the binary nature of the investment. For investors who believe in the commercial success of CRISPR therapies, NTLA could be a good buy at current levels, but only as a small, speculative position. Conservative investors should wait for revenue visibility or a pullback to a lower valuation.
NTLA is best suited for long-term investment (3-5 years) due to its pre-revenue status and binary nature. The stock's high beta of 1.77 and short ratio of 7.65 indicate significant short-term volatility, making it risky for short-term trading. The company has no dividend and negative free cash flow, so it does not provide income. The long-term thesis depends on the successful commercialization of its CRISPR platform, which could take several years to materialize. Short-term traders may profit from momentum, but the risk of sharp drawdowns is high. A minimum holding period of 3 years is recommended to allow the company to reach profitability and realize its revenue potential. For patient investors with a high risk tolerance, NTLA could offer substantial returns over the long term.
